1-6 of 6
Fadoua El Moustaid
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US)

Free
Zachary Frosch, Anthony Masaquel, Esprit Ma, Eric Zuk, Matthew Davis, Fadoua El Moustaid, Mei Wu, Carolina Reyes, Lourenia Cassoli, Scott Huntington
Journal: Blood
Blood (2025) 146 (Supplement 1): 2622.
https://doi.org/10.1182/blood-2025-2622
Published: 2025
Journal Articles

Estimated total cost of care and patient out-of-pocket cost savings with first-line fixed duration venetoclax + obinutuzumab compared with treat-to-progression BTKi regimens among Medicare-eligible patients with chronic lymphocytic leukemia in the United States following the Inflation Reduction Act.

Free
Sophia Li, Katherine Rosettie, Beenish Manzoor, Carolina Reyes, Fadoua El Moustaid
Journal: Blood
Blood (2025) 146 (Supplement 1): 4400.
https://doi.org/10.1182/blood-2025-4400
Published: 2025
Journal Articles

Economic and clinical impact of emicizumab in people with moderate and severe Hemophilia A in the US

Free
Janet Lee, Fadoua El Moustaid, Lucy Lee
Journal: Blood
Blood (2025) 146 (Supplement 1): 2610.
https://doi.org/10.1182/blood-2025-2610
Published: 2025
Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Free
David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 3646.
https://doi.org/10.1182/blood-2024-198451
Published: 2024
Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Free
Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch
Journal: Blood
Blood (2024) 144 (Supplement 1): 782.
https://doi.org/10.1182/blood-2024-198414
Published: 2024
Journal Articles

Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant

Free
David Fox, Fadoua El Moustaid, Anthony Masaquel, Katherine L Rosettie, Hazal Celik, Lourenia Cassoli, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 5027.
https://doi.org/10.1182/blood-2024-198461
Published: 2024